Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL

Cellular Oncology

Volumn 34, Issue 3, 2011, Pages 245-259

  Pennarun, Bodvael ^a   Kleibeuker, Jan H ^a   Oenema, Tjitske ^a   Stegehuis, Janet H ^a   De Vries, Elisabeth G E ^a   De Jong, Steven ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Colon cancer; DR4; DR5; PI3K; TRAIL

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CASPASE 8; DEATH RECEPTOR 5; NVP AEW 541; PHOSPHATIDYLINOSITOL 3 KINASE; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SOMATOMEDIN C RECEPTOR; CANCER ANTIBODY; CFLAR PROTEIN, HUMAN; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; FLICE INHIBITORY PROTEIN; NVP-AEW541; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ASSAY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; IMMUNOPRECIPITATION; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; WESTERN BLOTTING; BIOLOGICAL MODEL; COLON TUMOR; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTIBODIES, NEOPLASM; APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 8; CELL LINE, TUMOR; COLONIC NEOPLASMS; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEINS; ENZYME ACTIVATION; HUMANS; MODELS, BIOLOGICAL; PHOSPHATIDYLINOSITOL 3-KINASES; PYRIMIDINES; PYRROLES; RECEPTOR, IGF TYPE 1; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84555178469     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-011-0033-9     Document Type: Article

References (53)

1. D. Cunningham, W. Atkin, H.J. Lenz, H.T. Lynch, B. Minsky, B. Nordlinger, N. Starling, Colorectal cancer. Lancet 375, 1030-1047 (2010)
2. S. Kopetz, G.J. Chang, M.J. Overman, C. Eng, D.J. Sargent, D.W. Larson, A. Grothey, J.-N.Vauthey,D.M.Nagorney, R.R.McWilliams, Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27, 3677-3683 (2009)
3. E.W. Duiker, C.H. Mom, S. de Jong, P.H. Willemse, J.A. Gietema, A.G. van der Zee, E.G.E. de Vries, The clinical trail of TRAIL. Eur J Cancer 42, 2233-2240 (2006) (Pubitemid 44307615)
4. R.S. Herbst, S.G. Eckhardt, R. Kurzrock, S. Ebbinghaus, P.J. O'Dwyer, M.S. Gordon, W. Novotny, M.A. Goldwasser, T.M. Tohnya, B.L. Lum, A. Ashkenazi, A.M. Jubb, D.S. Mendelson, Phase I dose-escalation study of recombinant human Apo2L/ TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 28, 2839-2846 (2010)
5. J. Soria, E. Smit, D. Khayat, B. Besse, X. Yang, C. Hsu, D. Reese, J. Wiezorek, F. Blackhall, Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in CombinationWith Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer. J Clin Oncol 28, 1527-1533 (2010)
6. F.C. Kischkel, D.A. Lawrence, A. Tinel, H. LeBlanc, A. Virmani, P. Schow, Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 276, 46639-46646 (2001)
7. R.M. Pitti, S.A. Marsters, S. Ruppert, C.J. Donahue, A. Moore, A. Ashkenazi, Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271, 12687-12690 (1996) (Pubitemid 26175834)
8. S.R. Wiley, K. Schooley, P.J. Smolak, W.S. Din, C.P. Huang, J. K. Nicholl, G.R. Sutherland, T.D. Smith, C. Rauch, C.A. Smith, Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673-682 (1995) (Pubitemid 26091143)
9. A. Ashkenazi, R.C. Pai, S. Fong, S. Leung, D.A. Lawrence, S.A. Marsters, C. Blackie, L. Chang, A.E. McMurtrey, A. Hebert, L. DeForge, I.L. Koumenis, D. Lewis, L. Harris, J. Bussiere, H. Koeppen, Z. Shahrokh, R.H. Schwall, Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104, 155-162 (1999)
10. H. Walczak, R.E. Miller, K. Ariail, B. Gliniak, T.S. Griffith, M. Kubin, W. Chin, J. Jones, A. Woodward, T. Le, C. Smith, P. Smolak, R.G. Goodwin, C.T. Rauch, J.C. Schuh, D.H. Lynch, Tumoricidal activity of tumor necrosis factor-related apoptosisinducing ligand in vivo. Nat Med 5, 157-163 (1999) (Pubitemid 29068521)
11. R.F. Kelley, K. Totpal, S.H. Lindstrom, M. Mathieu, K. Billeci, L. DeForge, R. Pai, S.G. Hymowitz, A. Ashkenazi, Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 280, 2205-2212 (2005)
12. M. MacFarlane, S.L. Kohlhaas, M.J. Sutcliffe, M.J. Dyer, G.M. Cohen, TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res 65, 11265-11270 (2005) (Pubitemid 41821680)
13. A.M. van der Sloot, V. Tur, E. Szegezdi, M.M. Mullally, R.H. Cool, A. Samali, L. Serrano, W.J. Quax, Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci U S A 103, 8634-8639 (2006) (Pubitemid 43878072)
14. A. Chuntharapai, K. Dodge, K. Grimmer, K. Schroeder, S.A. Marsters, H. Koeppen, A. Ashkenazi, K.J. Kim, Isotypedependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 166, 4891-4898 (2001) (Pubitemid 32280698)
15. T.S. Griffith, C.T. Rauch, P.J. Smolak, J.Y. Waugh, N. Boiani, D. H. Lynch, C.A. Smith, R.G. Goodwin, M.Z. Kubin, Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol 162, 2597-2605 (1999) (Pubitemid 29309279)
16. K. Ichikawa, W. Liu, L. Zhao, Z. Wang, D. Liu, T. Ohtsuka, H. Zhang, J.D. Mountz, W.J. Koopman, R.P. Kimberly, T. Zhou, Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7, 954-960 (2001) (Pubitemid 32756434)
17. L. Pukac, P. Kanakaraj, R. Humphreys, R. Alderson, M. Bloom, C. Sung, T. Riccobene, R. Johnson, M. Fiscella, A. Mahoney, J. Carrell, E. Boyd, X.T. Yao, L. Zhang, L. Zhong, K.A. Von, L. Shepard, T. Vaughan, B. Edwards, C. Dobson, T. Salcedo, V. Albert, HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 92, 1430-1441 (2005) (Pubitemid 40705010)
18. A. Hague, D.J. Hicks, F. Hasan, H. Smartt, G.M. Cohen, C. Paraskeva, M. MacFarlane, Increased sensitivity to TRAILinduced apoptosis occurs during the adenoma to carcinoma transition of colorectal carcinogenesis. Br J Cancer 92, 736-742 (2005) (Pubitemid 40460611)
19. J.J. Koornstra, S. de Jong, H. Hollema, E.G.E. de Vries, J.H. Kleibeuker, Changes in apoptosis during the development of colorectal cancer: a systematic review of the literature. Crit Rev Oncol Hematol 45, 37-53 (2003) (Pubitemid 35449787)
20. R.W. Johnstone, A.J. Frew, M.J. Smyth, The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8, 782-798 (2008)
21. B. Pennarun, A. Meijer, E.G.E. de Vries, J.H. Kleibeuker, F.A. Kruyt, S. de Jong, Playing the DISC: Turning on TRAIL death receptor-mediated apoptosis in cancer. Biochim Biophys Acta Rev Cancer 1805, 123-140 (2010)
22. S.J. Cohen, R.B. Cohen, N.J. Meropol, Targeting signal transduction pathways in colorectal cancer-more than skin deep. J Clin Oncol 23, 5374-5385 (2005) (Pubitemid 46206991)
23. M. Cuello, S.A. Ettenberg, A.S. Clark,M.M.Keane, R.H. Posner, M. M. Nau, P.A. Dennis, S. Lipkowitz, Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factorrelated apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 61, 4892-4900 (2001) (Pubitemid 32691907)
24. C.S. Mitsiades, N. Mitsiades, V. Poulaki, R. Schlossman, M. Akiyama, D. Chauhan, T. Hideshima, S.P. Treon, N.C. Munshi, P. G. Richardson, K.C. Anderson, Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/ Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 21, 5673-5683 (2002) (Pubitemid 35333000)
25. S.Y. Park, D.W. Seol, Regulation of Akt by EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced TRAILinduced apoptosis. Biochem Biophys Res Commun 295, 515-518 (2002)
26. D. LeRoith, C.T. Roberts Jr., The insulin-like growth factor system and cancer. Cancer Lett 195, 127-137 (2003) (Pubitemid 36588961)
27. R. Baserga, F. Peruzzi, K. Reiss, The IGF-1 receptor in cancer biology. Int J Cancer 107, 873-877 (2003) (Pubitemid 37429826)
28. M.M. Weber, C. Fottner, S.B. Liu, M.C. Jung, D. Engelhardt, G.B. Baretton, Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer 95, 2086-2095 (2002) (Pubitemid 35253369)
29. W.H. Hu, H. Johnson, H.B. Shu, Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways. J Biol Chem 274, 30603-30610 (1999)
30. B.P. Zhou, M.C. Hu, S.A. Miller, Z. Yu, W. Xia, S.Y. Lin, M.C. Hung, HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 275, 8027-8031 (2000) (Pubitemid 30159714)
31. J. Luo, B.D. Manning, L.C. Cantley, Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4, 257-262 (2003) (Pubitemid 37329790)
32. K.A. West, S.S. Castillo, P.A. Dennis, Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 5, 234-248 (2002) (Pubitemid 36132805)
33. A. Gualberto, M. Pollak, Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 28, 3009-3021 (2009)
34. P. Workman, P.A. Clarke, F.I. Raynaud, R.L. van Montfort, Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res 70, 2146-2157 (2010)
35. C.S. Mitsiades, N.S. Mitsiades, C.J. McMullan, V. Poulaki, R. Shringarpure, M. Akiyama, T. Hideshima, D. Chauhan, M. Joseph, T.A. Libermann, A.A. Combining, M.A. Pearson, F. Hofmann, K.C. Anderson, A.L. Kung, Inhibition of the insulinlike growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5, 221-230 (2004) (Pubitemid 38402114)
36. E.H.Walker,M.E.Pacold,O. Perisic, L. Stephens, P.T.Hawkins,M.P. Wymann, R.L.Williams, Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 6, 909-919 (2000)
37. C.M.M. van Geelen, E.G.E. de Vries, T.K.P. Le, R.P. van Weeghel, S. de Jong, Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines. Br J Cancer 89, 363-373 (2003) (Pubitemid 36976328)
38. C.M.M. van Geelen, B. Pennarun, W. Boersma-Van Ek, P.T.K. Le, D.C. Spierings, E.G.E. De Vries, S. de Jong, Downregulation of active caspase 8 as a mechanism of acquired TRAIL resistance in mismatch repair-proficient colon carcinoma cell lines. Int J Oncol 37, 1031-1041 (2010)
39. I. Nicoletti, G. Migliorati, M.C. Pagliacci, F. Grignani, C. Riccardi, A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Meth 139, 271-279 (1991)
40. S. Hofbauer, G. Hamilton,G. Theyer, K.Wollmann, F. Gabor, Insulinlike growth factor-I-dependent growth and in vitro chemosensitivity of Ewing's sarcoma and peripheral primitive neuroectodermal tumour cell lines. Eur J Cancer 29A, 241-245 (1993)
41. B.C. Turner, B.G. Haffty, L. Narayanan, J. Yuan, P.A. Havre, A.A. Gumbs, L. Kaplan, J.L. Burgaud, D. Carter, R. Baserga, P.M. Glazer, Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 57, 3079-3083 (1997) (Pubitemid 27351714)
42. Y. Wu, M. Tewari, S. Cui, R. Rubin, Activation of the insulin-like growth factor-I receptor inhibits tumor necrosis factor-induced cell death. J Cell Physiol 168, 499-509 (1996) (Pubitemid 26302856)
43. K.G. Drosopoulos, M.L. Roberts, L. Cermak, T. Sasazuki, S. Shirasawa, L. Andera, A. Pintzas, Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway. J Biol Chem 280, 22856-22867 (2005) (Pubitemid 40853193)
44. L. Dubska, L. Andera,M.A. Sheard, HER2 signaling downregulation by trastuzumab and suppression of the PI3K/Akt pathway: an unexpected effect on TRAIL-induced apoptosis. FEBS Lett 579, 4149-4158 (2005) (Pubitemid 41021805)
45. D. Mahalingam, M. Keane, G. Pirianov, H. Mehmet, A. Samali, E. Szegezdi, Differential activation of JNK1 isoforms by TRAIL receptors modulate apoptosis of colon cancer cell lines. Br J Cancer 100, 1415-1424 (2009)
46. M. Remacle-Bonnet, F. Garrouste, G. Baillat, F. Andre, J. Marvaldi, G. Pommier, Membrane rafts segregate pro-from anti-apoptotic insulin-like growth factor-I receptor signaling in colon carcinoma cells stimulated by members of the tumor necrosis factor superfamily. Am J Pathol 167, 761-773 (2005) (Pubitemid 41216360)
47. D.J. Panka, T. Mano, T. Suhara, K. Walsh, J.W. Mier, Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J Biol Chem 276, 6893-6896 (2001)
48. M.H. Cardone, N. Roy, H.R. Stennicke, G.S. Salvesen, T.F. Franke, E. Stanbridge, S. Frisch, J.C. Reed, Regulation of cell death protease caspase-9 by phosphorylation. Science 282, 1318-1321 (1998) (Pubitemid 28524494)
49. S.R. Datta, H. Dudek, X. Tao, S. Masters, H. Fu, Y. Gotoh, M. E. Greenberg, Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91, 231-241 (1997) (Pubitemid 27456390)
50. L. del Peso, M. Gonzalez-Garcia, C. Page, R. Herrera, G. Nunez, Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278, 687-689 (1997) (Pubitemid 27464966)
51. L.R. Thomas, R.L. Johnson, J.C. Reed, A. Thorburn, The Cterminal tails of tumor necrosis factor-related apoptosisinducing ligand (TRAIL) and Fas receptors have opposing functions in Fas-associated death domain (FADD) recruitment and can regulate agonist-specific mechanisms of receptor activation. J Biol Chem 279, 52479-52486 (2004) (Pubitemid 39656624)
52. M. Hassan, O. Feyen, E. Grinstein, Fas-induced apoptosis of renal cell carcinoma is mediated by apoptosis signal-regulating kinase 1 via mitochondrial damage-dependent caspase-8 activation. Cell Oncol 31, 437-456 (2009)
53. S. Wang, W.S. El Deiry, Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc Natl Acad Sci U S A 100, 15095-15100 (2003) (Pubitemid 37518022)